Stem cell news is always burbling up, sometimes right there in front of us on the web and other times via networks of people. Astellas news. Some may remember there used to be this pioneering stem cell biotech called ACT, which then became Ocata, and finally was acquired by the big company Astellas. One of …
Stem cell news bites: Astellas trial, cystic fibrosis claim, a few cool papers Read More »
Do stem cells for vision loss offer real hope? I believe so, but it’s a long road and must be done right. A new paper in this area generated some buzz on top of an earlier recent pub (mentioned in this post) just a week or so ago about the potential of stem cells for vision …
Perspectives on new stem cells for vision loss paper Read More »
Each year I make a list of predictions for the year to come for the stem cell and regenerative medicine field. Then about a year later I grade myself on how I did as that year winds down. Here’s how I did in 2016. For 2017, late in 2016 I made 20 stem cell predictions. Let’s …
In December of each year I make a list of stem cell predictions for the coming year, and I made 20 such predictions for 2017 so I’m wondering how I’m doing so far on these now that it’s June. Below is my work-in-progress scorecard for these so far. Positive news from Asterias on trial for stem cell-based …
2017 stem cell predictions: score card at 1/2-way point Read More »
Late in 2015, one of the pioneering stem cell and regenerative medicine biotechs, Ocata Therapeutics (fka as ACT or Advanced Cell Technology) was acquired by Astellas Pharma. At the time of purchase, Ocata had a number of areas of focus, but was most closely followed for its development of human embryonic stem cell-based retinal pigmented epithelial …
Brief update from Bob Lanza on Astellas stem cell program Read More »
Each year I make a list of predictions for the stem cell and regenerative medicine field for the coming new year. Later in this post I list my top 20 stem cell predictions for 2017. In looking at my past predictions I realized this will now be my 7th year doing stem cell/regenerative medicine yearly predictions. …
Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions, …
Grading my stem cell predictions for 2016: how’d I do? Read More »
I received a score of great nominations for the Stem Cell Person of the Year 2016 Award and have briefly described the twenty nominees below. The point of the award is to honor the top positive stem cell leader who specifically thinks outside the box and takes risks. I’ve started an on-line vote where you can vote once per day for …
20 Nominees for Stem Cell Person of the Year 2016 Award Read More »
The money behind a piece of legislation can provide unique insights into the back story and this is definitely true for the REGROW Act that would reduce FDA oversight of the investigational use of stem cells in patients. Senator Mark Kirk of Illinois, who is facing probable defeat next week in his reelection bid according to …
REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises Read More »
Each December I make stem cell predictions for the coming year and I did that for 2016 where I made 20 predictions. At around mid year I do a checkup on how my predictions are doing halfway and that is the purpose of this post. Below are my predictions that I made in 2015 for stem …
Stem cell checkup: how are my 2016 predictions doing half way? Read More »